Every Form 4 that Dianthus Therapeutics, Inc. (DNTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics, Inc. (DNTH) executive Simrat Randhawa, EVP and Head of R&D, reported an exercise-and-sell transaction on September 1, 2026. Randhawa exercised stock options for 23,124 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share, then sold 23,124 shares of common stock in multiple open-market transactions at weighted average prices around $105–$107 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. The options exercised relate to awards that vest in equal monthly installments over four years beginning January 1, 2024, May 1, 2024, and January 1, 2025, respectively.
Dianthus Therapeutics, Inc. (DNTH) director Simon Read reported an option exercise-and-sale on common stock. He exercised 2,778 stock options at an exercise price of $18.36 per share, acquiring 2,778 shares of common stock, and on the same date sold 2,778 shares at a weighted-average price of $117.55 per share. The option exercise left 19,445 options reported as outstanding after the transaction, with the option expiring on May 22, 2035. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026, and the option award vests in three equal annual installments, subject to continued service.
Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share. This converted a stock option into directly held common shares.
The derivative position of 15,000 option shares was disposed of upon exercise, leaving Veness with 73,240 derivative securities reported following the transaction. The option award vested 25% on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.
Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock. On August 10, 2026, she exercised options for 7,750 shares of common stock at exercise prices of $19.36 and $11.20 per share, then sold 7,750 shares in multiple transactions at weighted average prices between $106.79 and $111.63 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
Dianthus Therapeutics (DNTH) director Simon Read exercised stock options for 2,777 shares of common stock at an exercise price of $18.36 per share, converting a Stock Option (Right to Buy) into common shares. On the same date, he reported six open-market sales totaling 2,777 shares at per-share prices including $107.11, $108.17, $108.95, $109.96, $111.05 and $111.77, each disclosed as a weighted average price across multiple trades within specified ranges. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following the option exercise, Read reported 22,223 option shares remaining under the same award, which vests in three equal annual installments, subject to continued service and an expiration date of May 22, 2035.
Dianthus Therapeutics executive Adam M. Veness, SVP, General Counsel and Secretary, exercised 20,000 stock options at an exercise price of $17.88 per share and sold the same number of common shares in open-market transactions at prices around $110–$111 per share. The trades on August 7 and 10, 2026 were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026. The options exercised are from an award vesting in equal monthly installments over four years after January 1, 2024.
Dianthus Therapeutics CEO and President Garcia Marino reported multiple insider trades dated August 7, 2026. He exercised stock options to acquire 166,000 shares of common stock at an exercise price of $8.44 per share, then on the same date sold 166,000 common shares in a series of open‑market or private transactions at weighted average prices such as $107.49, $108.05 and $110.76 per share. Footnotes state that the reported transaction was effected under a Rule 10b5‑1 trading plan adopted on May 8, 2026, and that the options, expiring June 6, 2032, began vesting on November 1, 2022 with the remainder vesting in equal monthly installments over three years, subject to continued service.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options for 31,249 shares of common stock at $21.77 per share on July 9, 2026, then sold the 31,249 shares in three open-market transactions at weighted average prices of $100.22, $101.24 and $101.97 pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these sales, he reported no directly held common shares and reported holdings of 68,751 stock options from an award that vests in equal monthly installments over four years after May 1, 2024.
Dianthus Therapeutics SVP and General Counsel Adam M. Veness reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 30,000 shares of common stock at a strike price of $17.88 per share, then sold 30,000 shares in open-market trades at weighted average prices of $80.34 and $81.38 per share. These sales were executed under a Rule 10b5-1 trading plan. Following the transactions, he held no shares of common stock directly but retained 80,000 stock options that continue to vest over four years beginning January 1, 2024.
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa reported option exercises and share sales in common stock. On June 1, 2026, Randhawa exercised stock options for a total of 26,530 shares of common stock at exercise prices between $8.44 and $22.07 per share.
On the same date, Randhawa sold 26,530 shares of common stock in open-market transactions at weighted average prices reported as $89.72, $90.72, and $91.37 per share, with actual trade prices ranging from $89.17 to $91.96. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, indicating the transactions were scheduled in advance.
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date.
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.
The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.
According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.
Dianthus Therapeutics director Anne McGeorge received a grant of stock options, not a market purchase or sale. The award covers 6,090 options to buy common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving the company through that vesting date.
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.
Dianthus Therapeutics director Jonathan Violin received a compensation-related stock option grant. He was awarded options to purchase 6,090 shares of common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that date. After this grant, he holds 6,090 stock options directly, with no open-market share purchases or sales reported in this filing.
Dianthus Therapeutics director Paula Soteropoulos received a grant of stock options covering 6,090 shares of common stock. These options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 derivative securities linked to common stock.
The underlying 6,090 shares of common stock will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through the vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Dianthus Therapeutics director Paula Soteropoulos reported an exercise-and-sale of 599 shares of common stock. She exercised stock options to acquire 599 shares at $8.44 per share, then sold 599 shares in the open market at $85.47 per share on May 8, 2026.
The stock option related to 599 underlying shares and had an expiration date of June 6, 2032. A footnote states the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.
The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. On March 31, 2026, he exercised options to acquire 114,367 shares of common stock, including 74,367 shares at an exercise price of $8.44 and 40,000 shares at $17.88 per share. He then sold 114,367 shares of common stock in a series of open-market transactions at weighted average prices ranging from about $78.33 to $85.54 per share, under a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these transactions, the filing shows he directly owns no shares of common stock.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options and sold the resulting shares. On March 31, 2026, she exercised options for 599 shares of common stock at $8.44 per share and immediately sold all 599 shares at $80.11 per share in an open-market transaction.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, the filing shows 0 common shares held directly from this transaction.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options for 27,594 shares of common stock at an exercise price of $8.44 per share and immediately sold the same 27,594 shares in an open-market transaction at $78.05 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she held no shares of common stock directly.
Dianthus Therapeutics CEO and President Garcia Marino exercised stock options on March 16, 2026 to acquire a total of 65,292 shares of common stock. This came from options for 59,700 shares at $6.70 per share and 5,592 shares at $17.88 per share. Following these exercises, Marino holds 65,292 common shares directly, while some option awards continue to vest over time according to their original schedules.
Dianthus Therapeutics CEO Garcia Marino reported an option exercise and related share sales. On March 12, 2026, he exercised stock options for 122,918 shares of common stock at an exercise price of $6.70 per share. The same day, he sold 122,918 shares of common stock in multiple open-market transactions at prices ranging from about $80.69 to $85.53 per share. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, he reported no directly held common shares and no remaining derivative position from this option grant.
Dianthus Therapeutics (DNTH) chief accounting officer Edward Carr exercised stock options and sold the resulting shares in a pre-planned series of trades. On March 12, 2026, he exercised options for 43,682 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share.
The same day, he sold 43,682 common shares in multiple open-market transactions at weighted-average prices ranging from about $80.71 to $85.53 per share. A footnote states these sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating the trades were pre-scheduled rather than opportunistic.
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction. The sale was executed at a price of $81.48 per share and made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following these transactions, Randhawa held no shares of common stock directly, according to the filing.
Dianthus Therapeutics reported a new equity award to its chief accounting officer, Edward Carr. On February 3, 2026, he received a stock option for 55,000 shares of common stock with an exercise price of $52.46 per share, expiring on February 3, 2036.
The option vests in equal monthly installments over four years after January 1, 2026, as long as he continues to serve the company on each vesting date. This filing reflects routine equity-based compensation rather than an open-market share purchase or sale.
Dianthus Therapeutics granted its SVP, General Counsel and Secretary, Adam Veness, a stock option for 100,000 shares of common stock on February 3, 2026. The option has an exercise price of $52.46 per share and was reported as directly owned.
The underlying common shares will vest in equal monthly installments over four years after January 1, 2026, as long as Veness continues serving the company on each vesting date. Following this award, he beneficially owned 100,000 derivative securities linked to Dianthus common stock.
Dianthus Therapeutics executive Simrat Randhawa, EVP and Head of R&D, reported a grant of stock options. On February 3, 2026, Randhawa received 150,000 stock options with an exercise price of $52.46 per share, all held directly.
The options relate to Dianthus common stock and begin vesting from January 1, 2026. They vest in equal monthly installments over four years, conditioned on Randhawa’s continued service with the company on each vesting date, and expire on February 3, 2036.
Dianthus Therapeutics reported a new equity award to its EVP, CFO & CBO, Ryan Savitz. On February 3, 2026, he received a stock option covering 150,000 shares of common stock with an exercise price of $52.46 per share and no cost at grant.
The option expires on February 3, 2036 and the underlying shares will vest in equal monthly installments over four years after January 1, 2026, as long as he continues serving the company on each vesting date. All 150,000 derivative securities are reported as directly owned following the transaction.
Dianthus Therapeutics CEO and President Marino Garcia reported a stock option grant. On February 3, 2026, he was awarded a Stock Option (Right to Buy) covering 355,000 shares of common stock at an exercise price of $52.46 per share.
The option was granted at no cost as a derivative security and is held directly. The underlying 355,000 shares will vest in equal monthly installments over four years after January 1, 2026, contingent on his continued service with Dianthus Therapeutics, Inc.
Marino Garcia, who serves as CEO and President and a director of Dianthus Therapeutics, Inc. (DNTH), was awarded a stock option on 09/30/2025 to purchase 120,000 shares of the company's common stock at an exercise price of $39.35 per share. The option is exercisable through 09/30/2035 and will vest in equal monthly installments over the four years following the grant, subject to the reporting person’s continued service. After the grant the reporting person beneficially owns 120,000 shares underlying the option on a direct basis.
Ryan Savitz, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc. (DNTH), was granted a stock option on September 23, 2025 to purchase 60,000 shares of common stock at an exercise price of $37.87 per share. The option vests in equal monthly installments over four years beginning on the grant date and expires on September 23, 2035. The reporting on Form 4 was signed by an attorney-in-fact on September 25, 2025. The award is reported as a direct beneficial ownership of 60,000 underlying shares immediately following the transaction.
Dianthus Therapeutics insider grant: Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics (DNTH), was granted a stock option on 09/23/2025 to purchase 60,000 shares of common stock. The option has an exercise/conversion price of $37.87 per share and an exercise/expiration date of 09/23/2035. The award vests in equal monthly installments over four years starting 09/23/2025, subject to continued service. The filing reports the holdings as 60,000 shares held directly following the transaction and is signed on behalf of the reporting person by an attorney-in-fact.